Ma HN, Cao KS, Liu YM, Chen C, Zhang H, Tang FS. Tenofovir amibufenamide: A potential alternative for chronic hepatitis B treatment. World J Gastroenterol 2025; 31(10): 102580 [DOI: 10.3748/wjg.v31.i10.102580]
Corresponding Author of This Article
Fu-Shan Tang, PhD, Professor, Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, No. 6 Xuefu West Road, Xinpu New District, Zunyi 563006, Guizhou Province, China. fstang@vip.163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Hai-Nan Ma, Kai-Sen Cao, Yan-Miao Liu, Cheng Chen, Hang Zhang, Fu-Shan Tang, Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi 563006, Guizhou Province, China
Hai-Nan Ma, Kai-Sen Cao, Yan-Miao Liu, Cheng Chen, Hang Zhang, Fu-Shan Tang, Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi 563006, Guizhou Province, China
Hai-Nan Ma, Kai-Sen Cao, Yan-Miao Liu, Cheng Chen, Hang Zhang, Fu-Shan Tang, Key Laboratory of Clinical Pharmacy in Zunyi City, Zunyi Medical University, Zunyi 563006, Guizhou Province, China
Author contributions: Ma HN and Cao KS contributed to the manuscript outline and composed the initial draft; Liu YM, Chen C, and Zhang H provided the method of literature retrieval; Tang FS originated the concept for this manuscript, provided supervision, reviewed the paper, and finalized the manuscript; and all authors have approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fu-Shan Tang, PhD, Professor, Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, No. 6 Xuefu West Road, Xinpu New District, Zunyi 563006, Guizhou Province, China. fstang@vip.163.com
Received: October 23, 2024 Revised: January 16, 2025 Accepted: February 8, 2025 Published online: March 14, 2025 Processing time: 126 Days and 12.8 Hours
Abstract
Tenofovir amibufenamide (TMF) is a novel prodrug of tenofovir that demonstrates a promising safety and efficacy profile. A recent study by Peng et al compared TMF with tenofovir alafenamide in the treatment of chronic hepatitis B. The findings indicated that both medications offer similar efficacy in terms of viral response and alanine aminotransferase normalization. Notably, TMF showed potential advantages in lipid management, as it did not significantly affect cholesterol levels, unlike tenofovir alafenamide. This correspondence highlights the need for further research to evaluate the long-term safety and efficacy of TMF, its impact on cardiovascular risk, and its use in specific patient populations.
Core Tip: Tenofovir amibufenamide demonstrates comparable efficacy to tenofovir alafenamide in the treatment of chronic hepatitis B. Tenofovir amibufenamide offers improved safety, particularly in lipid management, with minimal effects on bone and renal health. Its favorable metabolic profile makes it an attractive option for patients with hyperlipidemia, providing antiviral efficacy without compromising metabolic health. Large-scale, multicenter studies are essential to validate long-term outcomes and its suitability for special patient populations.
